Jerome B. Zeldis, Director at PTC THERAPEUTICS, INC. (PTCT), sold 48,000 shares at $52.39 ($2.5M) on 2024-12-02, disclosed to the SEC on 2024-12-04.
Scheduled sale ($2.5M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.52 | 5,699 | $288K | 11.6% |
| 2 | $50.52 | 5,699 | $288K | 11.6% |
| 3 | $51.43 | 2,634 | $135K | 5.5% |
| 4 | $51.43 | 2,634 | $135K | 5.5% |
| 5 | $51.44 | 8,813 | $453K | 18.3% |
| 6 | $51.44 | 8,813 |
| $453K |
| 18.3% |
| 7 | $52.39 | 3,667 | $192K | 7.8% |
| 8 | $52.39 | 3,667 | $192K | 7.8% |
| 9 | $52.42 | 3,187 | $167K | 6.8% |
| 10 | $52.42 | 3,187 | $167K | 6.8% |
| Total | $51.50 avg | 48,000 | $2.5M | 100% |
| Filing → |
| PTCT | SELL | 2024-05-24 | $765K | — | Filing → |
| NXGL | BUY | 2023-05-30 | $12K | — | Filing → |
| NXGL | BUY | 2022-03-28 | $10K | — | Filing → |